DMD and Duchenne muscular dystrophy: Thus, it can be concluded that the mitochondrial approach associated with reducing the calcium overload of the matrix of these organelles can be used for secondary therapy of Duchenne muscular dystrophy, but only as part of a complex therapy of this disease, affecting both the underlying cause (mutation in the gene and the absence of the dystrophin protein) and numerous secondary manifestations of the pathology.